MCID: ESP005
MIFTS: 16

Esophagus Carcinoma in Situ

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Esophagus Carcinoma in Situ

MalaCards integrated aliases for Esophagus Carcinoma in Situ:

Name: Esophagus Carcinoma in Situ 12 15
Carcinoma in Situ of Esophagus 12 73
Stage 0 Carcinoma of the Esophagus 12
Severe Esophageal Dysplasia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9095
ICD10 33 D00.1
ICD9CM 35 230.1
NCIt 50 C89771
UMLS 73 C0154059

Summaries for Esophagus Carcinoma in Situ

MalaCards based summary : Esophagus Carcinoma in Situ, is also known as carcinoma in situ of esophagus. An important gene associated with Esophagus Carcinoma in Situ is ODC1 (Ornithine Decarboxylase 1). The drugs Fentanyl and Pancreatic Polypeptide have been mentioned in the context of this disorder. Affiliated tissues include liver.

Related Diseases for Esophagus Carcinoma in Situ

Comorbidity relations with Esophagus Carcinoma in Situ via Phenotypic Disease Network (PDN):


Esophageal Disease

Symptoms & Phenotypes for Esophagus Carcinoma in Situ

Drugs & Therapeutics for Esophagus Carcinoma in Situ

Drugs for Esophagus Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
3 Analgesics Phase 3
4 Central Nervous System Depressants Phase 3
5 Adjuvants, Anesthesia Phase 3
6 Narcotics Phase 3
7 Analgesics, Opioid Phase 3
8 Anesthetics Phase 3
9 Anesthetics, General Phase 3
10 Anesthetics, Intravenous Phase 3
11 Peripheral Nervous System Agents Phase 3
12 Liver Extracts Phase 3
13 Cola Nutraceutical Phase 3
14
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
15
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
16
Fluorouracil Approved Phase 2 51-21-8 3385
17
Trioxsalen Approved Phase 2 3902-71-4 5585
18 Ether Phase 2
19 Albumin-Bound Paclitaxel Phase 2
20 Dermatologic Agents Phase 2
21 Dihematoporphyrin Ether Phase 2
22 Photosensitizing Agents Phase 2
23 Immunosuppressive Agents Phase 2
24 Antimetabolites Phase 2
25 Antimetabolites, Antineoplastic Phase 2
26 Antimitotic Agents Phase 2
27 Antineoplastic Agents, Phytogenic Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Photodynamic Therapy in Treating Patients With Early Esophageal Cancer Completed NCT00002935 Phase 2 porfimer sodium
3 Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer Completed NCT00281736 Phase 2 HPPH
4 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer Completed NCT00021320 Phase 2 cisplatin;fluorouracil;paclitaxel
5 Genetic and Environmental Risk Factors Related to Esophageal Cancer Recruiting NCT01035398

Search NIH Clinical Center for Esophagus Carcinoma in Situ

Genetic Tests for Esophagus Carcinoma in Situ

Anatomical Context for Esophagus Carcinoma in Situ

MalaCards organs/tissues related to Esophagus Carcinoma in Situ:

41
Liver

Publications for Esophagus Carcinoma in Situ

Variations for Esophagus Carcinoma in Situ

Expression for Esophagus Carcinoma in Situ

Search GEO for disease gene expression data for Esophagus Carcinoma in Situ.

Pathways for Esophagus Carcinoma in Situ

GO Terms for Esophagus Carcinoma in Situ

Sources for Esophagus Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....